BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that it will
be holding its Annual General and Special Meeting of Shareholders at 9 a.m. EDT
on Tuesday June 10, 2014 at the Sheraton Toronto Airport Hotel & Conference
Centre (Niagara Room) located at 801 Dixon Road, Toronto, Ontario, M9W 1J5.


Following the formal business of the meeting, CEO Rene Goehrum will be making a
presentation to attendees. Mr Goehrum will provide an overview of the Company
and its corporate activities.


To view and listen to a CEO presentation commenting on First Quarter 2014
Financial Results released May 16, 2014, please visit the following link
http://www.biosyent.com/q1/.


For a direct market quote (15 minutes delay) for the TSX Venture Exchange and
other Company financial information please visit www.tmxmoney.com.


About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them.


Once a product of interest has been found, BioSyent then acquires the exclusive
rights to the product and manages it through the Canadian governmental
regulatory approval process. Once approved, BioSyent markets the product
throughout Canada. 


At the date of this press release the Company had 13,801,195 shares issued and
outstanding.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.


The TSX Venture Exchange assumes no responsibility for the accuracy of this
release and neither approves nor disapproves of the same.


FOR FURTHER INFORMATION PLEASE CONTACT: 
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com

Biosyent (TSXV:RX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Biosyent Charts.
Biosyent (TSXV:RX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Biosyent Charts.